Corrigendum to "SAT-040 RENAL SAFETY OF DIRECT ACTING ANTIVIRAL DRUGS IN POST LIVER TRANSPLANT PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION" [Volume 5, Issue 3, Supplement, March 2020, Pages S18-S19].
「SAT-040 直接作用型抗病毒藥物於肝臟移植後慢性 C 型肝炎患者之腎臟安全性」更正啟事 [第5卷，第3期，增刊，2020年3月，S18-S19頁]
Kidney Int Rep 2025-06-09
Corrigendum to "WCN24-319 EFFICACY OF THERAPY WITH DOUBLE PLASMA MOLECULAR ADSORPTION SYSTEM IN SEVERE ACUTE LIVER INJURY SECONDARY TO CYTOMEGALOVIRUS: CASE REPORT" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Page S523-S524].
更正：「WCN24-319 雙重血漿分子吸附系統治療細胞增生病毒引起的嚴重急性肝損傷的療效：病例報告」 [<i>Kidney International Reports</i> 2024年4月第9卷第4期，補充資料，第S523-S524頁]。
Kidney Int Rep 2024-06-20
這篇文章的修正 DOI 是 10.1016/j.ekir.2024.02.1095。
PubMedDOI
Corrigendum to "WCN24-1051 CLINICAL PROFILE, DIAGNOSIS, THERAPEUTIC INTERVENTION AND COMPLICATIONS IN RENAL BIOPSY IN CKD POPULATION - SINGLE CENTER 20 YEARS' EXPERIENCE" [<i>Kidney International Reports</i> Volume 9, Issue 4, Supplement, April 2024, Page S86].
對於「WCN24-1051 CLINICAL PROFILE, DIAGNOSIS, THERAPEUTIC INTERVENTION AND COMPLICATIONS IN RENAL BIOPSY IN CKD POPULATION - SINGLE CENTER 20 YEARS' EXPERIENCE」的更正 [<i>Kidney International Reports</i> 第9卷，第4期，補充，2024年4月，第S86頁]。
Kidney Int Rep 2024-07-31
Corrigendum to "Safety and efficacy of semaglutide in post kidney transplants patients with type 2 diabetes or post-transplant diabetes" [J. Clin. Translat. Endoc. 36C (2024) 100343].
對於「Safety and efficacy of semaglutide in post kidney transplants patients with type 2 diabetes or post-transplant diabetes」的更正 [J. Clin. Translat. Endoc. 36C (2024) 100343]。
J Clin Transl Endocrinol 2025-01-07
Corrigendum to "WCN25-3808 NAFLD IN ESRD - PREVALENCE OF NAFLD in ESRD PATIENTS AND EVALUATION OF THERAPEUTIC EFFICACY OF TOCOTRIENOL IN TREATMENT OF NAFLD" [<i>Kidney International Reports</i> Volume 10, Issue 2, Supplement, February 2025, Pages S339-S340].
更正啟事：「WCN25-3808 末期腎臟病（ESRD）中的非酒精性脂肪肝病（NAFLD）—ESRD 患者中 NAFLD 的盛行率及 tocotrienol 治療 NAFLD 療效之評估」[《Kidney International Reports》2025年2月，第10卷，第2期，增刊，S339-S340頁]
Kidney Int Rep 2025-04-30
Erratum to "Anticoagulation for the Prevention of Thrombotic Events in Nephrotic Syndrome" [<i>Kidney International Reports</i> Volume 9, Issue 10, October 2024, Pages 3053-3056].
「『Anticoagulation for the Prevention of Thrombotic Events in Nephrotic Syndrome』一文的勘誤啟事」
Kidney Int Rep 2025-04-30
Corrigendum to "Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy" [Volume 10, Issue 1, January 2025, Pages 217-226].
更正啟事：「ALIGN 隨機對照研究 Atrasentan 用於 IgA Nephropathy 患者之研究設計與基線特徵」[第10卷，第1期，2025年1月，頁217-226]
Kidney Int Rep 2025-04-30
重點摘要：
這則通知是用來更正 DOI 為 10.1016/j.ekir.2024.10.004 的文章。內容很可能是針對該篇發表的錯誤進行修正，或是提供相關的最新更新。
PubMedDOI
Correction to: The ERA Registry Annual Report 2022: Epidemiology of Kidney Replacement Therapy in Europe, with a focus on sex comparison.
更正：ERA Registry 2022 年度報告：歐洲腎臟替代治療流行病學，聚焦性別比較
Clin Kidney J 2025-05-07
Corrigendum to "The Bromodomain and Extraterminal Protein Inhibitor Apabetalone Ameliorates Kidney Injury in Diabetes by Regulating Cholesterol Accumulation and Modulating the Gut Microbiota" [Volume 10, Issue 2, February 2025, Pages 522-534].
「更正啟事：'Bromodomain and Extraterminal Protein Inhibitor Apabetalone 透過調節膽固醇累積及腸道菌相，改善糖尿病腎損傷'【第10卷，第2期，2025年2月，522-534頁】」
Kidney Int Rep 2025-06-09
Corrigendum to "PREGNANCY AS A WINDOW TO CURRENT AND FUTURE KIDNEY HEALTH-AN OPPORTUNITY" [Volume 10, Issue 3, March 2025, Pages 645-649].
「PREGNANCY AS A WINDOW TO CURRENT AND FUTURE KIDNEY HEALTH-AN OPPORTUNITY」[第10卷，第3期，2025年3月，第645-649頁]之更正啟事
Kidney Int Rep 2025-06-09
Corrigendum to "Outcomes of Living Kidney Donors Following Donor Nephrectomy in Aotearoa New Zealand" [Volume 10, Issue 3, March 2025, Pages 762-771].
「更正啟事：Aotearoa New Zealand 活體腎臟捐贈者於捐腎手術後之預後分析」【第10卷，第3期，2025年3月，頁762-771】
Kidney Int Rep 2025-06-09